Hyloris Pharmaceuticals, Rosemont Pharmaceuticals Sign US Licensing, Supply Deal for Atomoxetine Oral Solution

11:43 PM EST, 12/29/2025 (MT Newswires) -- Hyloris Pharmaceuticals (HYL.BR) entered an exclusive out-licensing and supply agreement with Rosemont Pharmaceuticals to commercialize its Atomoxetine Oral Solution in the US. Under the terms of the deal, the specialty biopharma company will be responsible for product approval and supply, and be eligible to receive milestone payments and sales-based royalties, according to a Monday release. The Atomoxetine Oral Solution offers an alternative to existing oral atomoxetine capsules for patients with attention deficit hyperactivity disorder who have trouble swallowing solid oral dosage forms or require individualized dose titration.